Option chain shows key data for Predictive Oncology's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Predictive Oncology.

Predictive Oncology (NASDAQ:POAI) Stock, Option Chain

Predictive Oncology

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

xr:d:DAFqNaIkdw0:2,j:153520640059868796,t:23073113

News

Intraday Update

Markets

Movers

Trading Ideas

AEYE

ATUS

AVGR

AVTR

BIIB

BJRI

CHTR

CMAX

COLB

COUR

CREV

DECK

DOUG

DXCM

EVRI

FWRD

GROM

KARO

KITT

LBRDA

NMHI

Next Technology Holding Inc. - Ordinary Shares

NXTT

OPTT

PAPL

POAI

PSIG

SAIA

SDST

SGMO

SLNA

TANH

TARS

TNDM

TWOU

UCTT

VSAT

WINT

WRLD

ZYXI

Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

ASTS

ATPC

BALY

BLMZ

CERO

COOP

CTNT

EZFL

FORM

GSHD

HOTH

INDV

JBHT

KALU

KDLY

LULU

PEGA

PLXS

RBBN

SHYF

SLGL

SLRX

STLA

TIVC

VKTX

XCUR

Why Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Medicine,Doctor,Touching,Electronic,Medical,Record,On,Tablet.,Dna.,Digital

Predictive Oncology shares are blasting higher Thursday after the company announced it is expanding its AI and machine learning driven drug discovery platform to pursue discovery of novel biomarkers. Here&#39;s a look at what&#39;s going on:

Why Predicitive Oncology Stock Is Soaring

Predictive Oncology Inc

13F Shows JANA Partners Exited Position In BlackLine Inc, Previously Holding 1,154,435 Shares

Wells Fargo analyst Michael Blum maintains Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) with a Equal-Weight and lowers the price target from $3 to $2.

Price Target

Analyst Ratings

PLUG

Wells Fargo Maintains Equal-Weight on Plug Power, Lowers Price Target to $2

WIIM

SCHW

Charles Schwab shares are trading higher after the company reported a year-over-year increase in core net new assets and provided updates on its transaction sweep cash balance.

FYBR

13F Shows JANA Partners Decreased Stake In Frontier Communications Parent From 9,577,733 Shares To 3,910,213 Shares

<ul>
<li>The number of separate treatment applications a patient can receive was raised from 4 to 8</li>
<li>Treatment duration increased from 12 to 16 weeks
<ul>
<li>Importantly, the MACs have maintained their insistence on well-powered, peer-reviewed clinical evidence as a prerequisite for reimbursement.</li>
</ul>
</li>
</ul>

Biotech

General

MDXG

MiMedx Group Provides Update On Local Coverage Determinations; Raises Separate Treatment Applications A Patient Can Receive From 4 To 8; Increased Treatment Duration From 12 To 16 Weeks

Earnings

Safe and Green Development Q3 Revenues $81,210, GAAP Net Loss ($2,342,002)

Cantor Fitzgerald analyst Derek Soderberg reiterates Complete Solaria (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>) with a Overweight and maintains $6 price target.

Reiteration

CSLR

Cantor Fitzgerald Reiterates Overweight on Complete Solaria, Maintains $6 Price Target

13F Shows JANA Partners Increased Stake In Rapid7 Inc From 2,724,386 Shares To 3,655,540 Shares

Wells Fargo analyst Ike Boruchow maintains Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) with a Overweight and lowers the price target from $175 to $165.

ROST

Wells Fargo Maintains Overweight on Ross Stores, Lowers Price Target to $165

TRMB

13F Shows JANA Partners Increased Stake In Trimble From 4,177,544 Shares To 4,880,944 Shares

Piper Sandler analyst Allison Bratzel maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Neutral and raises the price target from $15 to $23.

RIGL

Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $23

ASML

ASML shares are trading higher. At Investor Day, the CEO provided forecasts that the global chip market will grow at 9% per year and pass $1 trillion by 2030.

Spire Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) agreed to sell its maritime business to Kpler for <a href="https://www.benzinga.com/news/asset-sales/24/11/41944207/spire-global-soars-on-heels-of-241-million-sale-of-maritime-business-plans-debt-payoff">roughly $241 million</a>.
The deal includes a $233.5 million purchase price and $7.5 million allocated for services over the next twelve months post-closing. This valuation reflects roughly 5.8 times the revenue generated by the maritime business over the past year.
Peter Platzer, Spire CEO said, "We are now even better equipped with the resources, technology and experience to serve governments and commercial clients to fulfill their missions, whether through our advanced data solutions or empowering them with our sophisticated space services offering…In addition to these benefits for Spire, we expect this sale will benefit our maritime customers and team members by allowing our maritime business to grow even faster within a global organization leading the digitalization of the maritime industry,"
Spire shares gained 14.1% to close at $13.45 on Wednesday.
These analysts made changes to their price targets on Spire following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5898636e43eaaa00018b14b0/jeffrey-meuler">Baird analyst Jeffrey Meuler</a> maintained Spire Global with a Neutral and raised the price target from $9 to $16.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/591479b9290fa7000138e4bb/jeff-van%20rhee">Craig-Hallum analyst Jeff Van Rhee </a>upgraded Spire Global from Hold to Buy and raised the price target from $8 to $20.</li>
</ul>
Considering buying SPIR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="588" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14091422/image-155-1024x588.png" alt="" class="wp-image-648045" style="width:639px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14091422/image-155-1024x588.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14091422/image-155-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14091422/image-155-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14091422/image-155.png 1126w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41962884/us-stocks-settle-mixed-following-inflation-data-investor-sentiment-improves-but-fear-index-remains-in-greed-zone">US Stocks Settle Mixed Following Inflation Data: Investor Sentiment Improves, But Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

SPIR

These Analysts Boost Their Forecasts On Spire Global

FBLG

FibroBiologics Files Patent Application To Reduce Blood Clotting Risks In Cell-Based Therapies, Targeting IBMIR-Mediated Inflammatory And Coagulative Responses To Enhance Safety And Effectiveness

Cheetah Net Supply Chain's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NYSE">CTNT</a>) short percent of float has fallen 81.99% since its last report. The company recently reported that it has 138 thousand shares sold short, which is 9.67% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cheetah Net Supply Chain Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731593722_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cheetah Net Supply Chain has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cheetah Net Supply Chain's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cheetah Net Supply Chain's peer group average for short interest as a percentage of float is 7.01%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Cheetah Net Supply Chain's Recent Short Interest

Piper Sandler analyst Allison Bratzel maintains Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) with a Overweight and lowers the price target from $65 to $62.

IONS

Piper Sandler Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $62

Long before billionaire Mark Cuban splurged on NBA teams and private jets, <a href="https://www.benzinga.com/personal-finance/24/08/40442345/mark-cuban-says-he-drove-cars-that-cost-200-with-holes-in-the-floorboard-and-lived-off-mac-and-c">he drove cars that cost less than $200 – </a>one of which he even found abandoned. Reflecting on his early days in a December 2022 episode of the Club Random Podcast with Bill Maher, Cuban shared how his passion for financial independence drove him to make unique choices with money and his lifestyle.
Don't Miss:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
<li><a href="https://www.benzinga.com/money/100k-cd">$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</a></li>
</ul>
In 1982, fresh out of Indiana and chasing opportunities in Dallas, Cuban's 1977 Fiat X1/9 broke down, leaving him without a car. To make things worse, the Fiat had holes in the floorboard, making it unreliable and dangerous. Without a reliable vehicle and limited funds, Cuban relied on friends to get around until, one day, he stumbled on a surprising opportunity: a car abandoned on the side of the road.
He immediately made his friends pull over. He spotted an envelope stuffed with loan documents on the front seat inside the unlocked car. Realizing someone likely gave up the car due to missed payments, Cuban had an idea. "I knew from my own personal experience that someone had abandoned [the car] because they couldn't make the payment," he told Maher. With his history of bad credit and a deep understanding of financial struggles, Cuban took a chance. The next day, he called the bank, explained he'd found the car and asked if he could take over payments. Incredibly, they agreed and Cuban was back on the road.
Trending: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
Of course, this "strategy" isn't exactly replicable today, as Cuban pointed out to Maher. In the digital age, speaking directly with a bank to make a deal like this is nearly impossible and finding an abandoned car with paperwork intact is just as rare. However, Cuban's resourcefulness and determination to live affordably still hold valuable lessons for anyone hoping to save big.
This car saga is just one example of how creatively Cuban lived on a tight budget. At 24, he shared a three-bedroom apartment with five roommates, eating macaroni and cheese and scoring supermarket discounts to keep his expenses low. Cuban told Maher he used to shop for food at midnight when grocery stores slashed prices on certain items. "I used to go to the grocery store at midnight because they lowered the price of chicken and these big [bags of] french fries to $1.29," Cuban recalled. "And I would buy a bunch of them."
See Also: According to Vanguard&#8217;s Advisor&#8217;s Alpha Study, working with a financial advisor can result in approximately 3% higher net returns annually,<a href="https://www.benzinga.com/money/3-percent-advantage-financial-advisor"> here are the benefits of partnering with a financial advisor and how to find the right one near you in minutes.</a>
His lean lifestyle went beyond his living situation and diet, though. It was grounded in a bigger goal: financial independence. In a 2017 Money interview, Cuban reflected on his younger self, "I was determined to be able to retire. I valued time more than anything. I wanted enough money to travel, have fun and party like a rock star <a href="https://www.benzinga.com/personal-finance/24/09/40752828/mark-cuban-shares-he-reached-first-1-million-by-learning-to-party-like-a-rock-star-but-still-liv">but still live like a student</a>. That was my motivation."
Cuban's relentless drive eventually <a href="https://www.benzinga.com/startups/24/10/41120122/mark-cuban-getting-filthy-stinkin-rich-is-one-of-the-most-patriotic-things-you-can-do-thats-the-amer">led to his big break</a>. After years of hustling, he launched a software company called MicroSolutions, which he sold for $6 million in 1990. This set him on the path to building the immense fortune he has today, estimated at $5.1 billion. His next big move came in 1999 when he sold his second company, Broadcast.com, to Yahoo for nearly $6 billion, cementing his status as one of the world's wealthiest self-made billionaires.
For those hoping to achieve financial freedom, Cuban's story is a reminder that the path isn't always glamorous, but strategic frugality and ambition can set a strong foundation. Just remember, <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">consulting a financial advisor</a> can help you make the most of your resources while avoiding some of the tougher financial hurdles Cuban faced.
Read Next:
<ul>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>

Personal Finance

Mark Cuban Drove An Abandoned Car He Found After His $200 Fiat With Holes In The Floorboard Died – 'I Was Determined To Be Able To Retire'

Innodata's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NYSE">INOD</a>) short percent of float has fallen 7.31% since its last report. The company recently reported that it has 3.81 million shares sold short, which is 14.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Innodata Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731593717_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Innodata has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Innodata's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Innodata's peer group average for short interest as a percentage of float is 2.44%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

INOD

How Is The Market Feeling About Innodata?

Norfolk Southern's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) short percent of float has risen 6.59% since its last report. The company recently reported that it has 2.19 million shares sold short, which is 0.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.65 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Norfolk Southern Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731593711_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Norfolk Southern has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Norfolk Southern's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Norfolk Southern's peer group average for short interest as a percentage of float is 7.64%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Norfolk Southern's Recent Short Interest

Bilibili Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) reported fiscal third-quarter revenue of $1.04 billion (7.31 billion Chinese yuan), up by 26% year-on-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41965225/bilibili-inc-announces-third-quarter-2024-financial-results" rel="noreferrer noopener">analyst consensus estimate of $1.01 billion</a>.&nbsp;
The Chinese video-sharing&nbsp;platform's&nbsp;adjusted EPADS of $0.08 missed the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus loss estimate of $0.10</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41939018/japan-increases-semiconductor-funding-as-us-trade-policies-pressure-taiwan-semiconductor" rel="noreferrer noopener">Japan Increases Semiconductor Funding As US Trade Policies Pressure Taiwan Semiconductor</a>
Drivers: Average daily active users (DAUs) climbed 4.4% Y/Y to 107.3 million. Revenues from mobile games were $259.7 million, up by 84%&nbsp;Y/Y, mainly attributable to the strong performance of the company's exclusively licensed game,&nbsp;San Guo: Mou Ding Tian Xia.
Value-added services (VAS) revenues grew 9% Y/Y to $402.0 million, led by increases in revenues from live broadcasting and other value-added services.
Advertising increased by 28%&nbsp;Y/Y&nbsp;to $298.5 million, mainly attributable to the company's improved advertising product offerings and enhanced advertising efficiency.
Revenue from IP derivatives and others decreased 2%&nbsp;Y/Y&nbsp;to $80.8 million.
Adjusted net profit&nbsp;was $33.6 million. Bilibili held $2.17 billion in cash and equivalents as of September. It generated $317.1 million in operating cash flow for the quarter.
Share Buyback: The board of directors has authorized a share repurchase program under which the company can repurchase up to $200 million of its publicly traded securities for the next 24 months.
Bilibili Chairman and CEO Rui Chen reported strong growth across community metrics and core business segments this quarter. Daily active users (DAUs) and monthly active users (MAUs) reached record highs of 107 million and 348 million, respectively. The average daily time spent by users increased to 106 minutes, up by 6 minutes from the same period last year. Chen highlighted the company's success in boosting user engagement and driving value through a variety of commercial offerings. He emphasized that achieving the first adjusted net profit marks a significant milestone, setting the stage for further development of commercialization efforts and continued growth.
CFO Sam Fan noted strong performance in high-margin segments like mobile games and advertising, which accelerated overall revenue growth and improved profitability. Gross profit jumped 76% year-over-year, with the gross margin rising to 34.9% from 25.0% in the same period last year.
Bilibili stock surged over 83% year-to-date.
Price Action:&nbsp;BILI stock is down 5.67% at $20.07 premarket at&nbsp;the last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41938753/cyberark-q3-earnings-subscription-growth-soars-arr-up-new-cfo-announced-and-more" target="_blank" rel="noreferrer noopener">CyberArk Q3 Earnings: Subscription Growth Soars, ARR Up, New CFO Announced And More</a></li>
</ul>
Image via Shutterstock

Emerging Markets

Buybacks

Tech

BILI

Bilibili's Q3 Earnings: Revenue Surges As Games Lead the Way, Stock Buyback And More

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Shares of biotechnology specialist Predictive Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/poai-stock-quote/">POAI</a>) &mdash; which leverages artificial intelligence (AI) and machine learning models for the discovery of novel biomarkers in cancer research protocols &mdash; soared on Thursday. Earlier, the company announced a major development in terms of the predictability models of ovarian cancer. Therefore, POAI stock jumped higher on the credibility boost.



According to the biotech firm&rsquo;s <a href="https://finance.yahoo.com/news/predictive-oncology-enters-biomarker-discovery-110000330.html">press release</a>, a retrospective ovarian cancer study with UPMC Magee-Womens Hospital (based in Pittsburgh, Pennsylvania) demonstrated that Predictive&rsquo;s ML models can more accurately forecast short-term and long-term survival outcomes compared to clinical data alone.



Fundamentally, this development has brought much excitement to POAI stock because Predictive&rsquo;s deep learning protocol &mdash; combined with a diverse biobank of patient samples &mdash; may help accelerate biomarker discovery tied to patient survival and therapeutic response.



In addition, the underlying technology can act as a force multiplier, advancing the development of clinical support tools. The innovation may also allow for more efficient screening for clinical trial enrollment.



<h2>Massive Addressable Market Bodes Well for POAI Stock</h2>



Beyond the clinical implications, POAI stock soared on the underlying massive total addressable market. According to the release, the biomarker discovery market may end up with a valuation of $51.5 billion by year&rsquo;s end. Right now, the market capitalization of Predictive sits at $7.14 million.



Further, the sector might only expand from here on out. Data from Grand View Research states that the global biomarker ecosystem was already worth $81.04 billion last year. Whatever the case, experts project that the industry could expand at a <a href="https://www.grandviewresearch.com/industry-analysis/biomarkers-industry">compound annual growth rate of 13.36%</a> by 2030. By the forecast culmination point, it may be worth $194.21 billion.



Again, with POAI stock featuring just a morsel of the growing pie, the opportunity for speculators is immense. Still, it must also be acknowledged that Predictive represents a highly speculative investment.



Since the start of the year, POAI stock dropped more than 50% in value. That&rsquo;s inclusive of today&rsquo;s blistering run. Further, in the past 52 weeks, POAI suffered a drop of 64%. Not surprisingly, Wall Street analysts currently do not cover Predictive Oncology. Still, that might change due to the equity&rsquo;s strong performance and significant credibility boost.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-predictive-oncology-poai-stock-up-70-today/">Why Is Predictive Oncology (POAI) Stock Up 70% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Predictive Oncology (POAI) Stock Up 70% Today?

Predictive Oncology looks to raise $1.3M through exercise of warrants

Here's the major earnings before the open tomorrow

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Predictive Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/poai-stock-quote/">POAI</a>) just reported results for the second quarter of 2024.<ul><li>Predictive Oncology reported earnings per share of -68 cents.</li><li>The company reported revenue of $278,722.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/poai-stock-earnings-predictive-oncology-for-q2-of-2024/">POAI Stock Earnings: Predictive Oncology Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

POAI Stock Earnings: Predictive Oncology Reported Results for Q2 2024

Predictive Oncology GAAP EPS of -$0.68, revenue of $0.28M

Predictive Oncology Inc. (POAI) Q2 2024 Earnings Call Transcript

Predictive Oncology files to sell 1.98M shares of common stock for holders

Predictive Oncology (POAI – Research Report) received a Buy rating and a $3.00 price target from H.C. Wainwright analyst Swayampakula Ramakanth tod...

H.C. Wainwright Initiates a Buy Rating on Predictive Oncology (POAI)

Predictive Oncology GAAP EPS of -$0.36 misses by $0.10, revenue of $0.35M in-line

Predictive Oncology Inc ( ($POAI) ) has released its Q3 earnings. Here is a breakdown of the information Predictive Oncology Inc presented to its i...

Predictive Oncology Inc. Reports Q3 2024 Earnings

ARCO

BCLI

BKKT

BLUE

CRMD

DOLE

EONGY

ESLT

FLNG

GLBE

HNHAF

IMNN

IPWR

ITRM

KMDA

KPLT

MDWD

MEDIF

MGIC

ONDS

OTLK

PFGC

PRPH

RSKD

SACH

SUNS

TCEHY

TSAT

VISL

VWDRY

WKHS

Health Care

Press Releases

Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery

Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)

Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results

Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds

Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024

Predictive Oncology Expands the Application of its Live-Cell Tumor Platform to De-Risk Drug Discovery and Accelerate Pipeline Development

Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update

Predictive Oncology Study Demonstrates Long-Term Stability and Viability of Proprietary Biobank of Primary Tumor Specimens for Pharmaceutical Drug Discovery

Predictive Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update

Aethlon Medical

Autonomix Medical

Comments

Predictive Oncology

Predictive Oncology (POAI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga